Megan M. Tu

HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib

Y. Wang, Tao Jiang, Zhen Qin et al. · Annals of Oncology · 2018 · 217 citations · Full text

Medicine, Oncology, Pharmacology +15

Inhibition of the CCL2 receptor, CCR2, enhances tumor response to immune checkpoint therapy

Megan M. Tu, Hany Abdel-Hafiz, Robert T. Jones et al. · Communications Biology · 2020 · 172 citations · Full text

Life Sciences, Immunology, Oncology +17

Targeting DDR2 enhances tumor response to anti–PD-1 immunotherapy

Megan M. Tu, Francis Y. F. Lee, Robert T. Jones et al. · Science Advances · 2019 · 127 citations · Full text

Medicine, Immunology, Oncology +17

ROS1 Gene Rearrangements Are Associated With an Elevated Risk of Peridiagnosis Thromboembolic Events

Terry L. Ng, Derek Smith, Rao Mushtaq et al. · Journal of Thoracic Oncology · 2018 · 74 citations

Medicine, Genetics, Molecular Genetics +9

A Viral Immunoevasin Controls Innate Immunity by Targeting the Prototypical Natural Killer Cell Receptor Family

Oscar A. Aguilar, Richard Berry, Mir Munir A. Rahim et al. · Cell · 2017 · 73 citations · Full text

Life Sciences, Immunology, Infectious Diseases +12